Trial Profile

A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 May 2016 Results (pooled analysis of this and other study, n = 98) assessing safety and efficacy of daclatasvir Plus sofosbuvir with or without ribavirin in patients with advanced fibrosis or cirrhosis presented at the Digestive Disease Week 2016.
17 Apr 2016 Results (sequencing analysis, n = 17) presented at The International Liver Congress™ 2016.
17 Apr 2016 Pooled safety and efficacy analysis of ALLY-3 and ALLY-3+ studies (n=168) were presented at The International Liver Congress 2016.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com